SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

BTAI

BioXcel Therapeutics, Inc.
NASDAQHealth Care

Latest close: 0.05 USD · Oct 8, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 1, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 28, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 25, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year244
SEC filings on record64110 flagged findings
Reported transactions (Form 4)80since Sep 14, 2025 · and 33 other holdings
Corporate events (8-K)30since Dec 6, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Listing notice in force

The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of Sep 1, 2026).

  • unspecified type · Nasdaq, rule 5110(b) · notice of Aug 31, 2026 · delisting determination · deadline not determined

Open the 8-K at the SEC

Reverse splits in 5 years

1 reverse split in 5 years (1:16 on Feb 10, 2025) · 1:16 cumulative

The other times: of 814 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 380 lost more than half and 209 rose (806 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 641)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 1, 268-K ↗Current report · Listing notice (8-K 3.01)
  • Aug 28, 268-K ↗Current report · Bankruptcy or receivership proceedings
  • Aug 25, 268-K ↗Current report · Entered a material agreement
  • Aug 24, 268-K ↗Current report · Entered a material agreement
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Armistice Capital, LLC · 5.0% · event on Jun 30, 26 · amendment
  • Aug 14, 26Form 4 ↗Insider transaction
  • Aug 14, 26Form 3 ↗Insider transaction
  • Aug 13, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Entered a material agreement
  • Aug 3, 268-K ↗Current report · Entered a material agreement
  • Jul 6, 268-K ↗Current report · Entered a material agreement
  • Insider transaction · 8 Form 4 filingsshow all 8hide
  • Notice of proposed sale · 4 Form 144 filingsshow all 4hide
  • May 15, 26SCHEDULE 13G ↗Passive stake · Armistice Capital, LLC · 7.0% · event on Mar 31, 26
  • May 15, 268-K ↗Current report · Results

641 filings on record, the oldest from Dec 12, 17.

Listing the 25 most recent filings of the 641 on record.

8-Ks, explained

Stress5Structure34Governance17
  • Sep 1, 26StressListing notice (8-K 3.01)+1 more in the same filing · the filing reports the decision to delist8-K 3.01 ↗
  • Aug 28, 26StressBankruptcy or receivership proceedings+1 more in the same filing8-K 1.03 ↗
  • Structure5 material agreements entered2026show all 5hide
    • Aug 25, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Aug 24, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Aug 11, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Aug 3, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Jul 6, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Apr 17, 26StructureSold unregistered shares+1 more in the same filing8-K 3.02 ↗
  • Mar 11, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Feb 6, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Apr 3, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Mar 21, 25StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Mar 4, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 16, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Jan 8, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Nov 25, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗

8 older filings not shown · The record reaches back to Mar 13, 18.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Sep 20, 24StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 19, 24StressRestructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗

The full record holds 5 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Integrated Core Strategies (US) LLC8.4%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Oaktree Capital Group Holdings GP, LLC5.2%Nov 25, 24SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Armistice Capital, LLC5.0%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Oaktree Capital Holdings, LLC2.7%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Qatar Investment Authority0.6%Dec 31, 25SCHEDULE 13G/A ↗1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • May 20, 26Sell$21KVimal MehtaCEO and President↗
  • May 20, 26Sell$7KRichard I SteinhartChief Financial Officer↗
  • May 20, 26Sell$7KJavier RodriguezSee Remarks↗
  • May 20, 26Sell$7KFrank YoccaChief Scientific Officer↗
Stock compensation, tax and giftsshow the 36 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jun 15, 26Compensationamount n/aVimal MehtaCEO and President↗
  • Jun 15, 26Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Jun 15, 26Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Jun 15, 26Compensationamount n/aJavier RodriguezSee Remarks↗
  • May 4, 26Compensationamount n/aVimal MehtaCEO and President↗
  • May 4, 26Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • May 4, 26Compensationamount n/aJavier RodriguezSee Remarks↗
  • May 4, 26Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • May 1, 26Compensationamount n/aJavier RodriguezSee Remarks↗
  • May 1, 26Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • May 1, 26Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • May 1, 26Compensationamount n/aVimal MehtaCEO and President↗
  • Mar 15, 26Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Mar 15, 26Compensationamount n/aJavier RodriguezSee Remarks↗
  • Mar 15, 26Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Mar 15, 26Compensationamount n/aVimal MehtaCEO and President↗
  • Mar 14, 26Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Mar 14, 26Compensationamount n/aJavier RodriguezSee Remarks↗
  • Mar 14, 26Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Mar 14, 26Compensationamount n/aVimal MehtaCEO and President↗
  • Dec 15, 25Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Dec 15, 25Compensationamount n/aJavier RodriguezSee Remarks↗
  • Dec 15, 25Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Dec 15, 25Compensationamount n/aVimal MehtaCEO and President↗
  • Dec 14, 25Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Dec 14, 25Compensationamount n/aJavier RodriguezSee Remarks↗
  • Dec 14, 25Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Dec 14, 25Compensationamount n/aVimal MehtaCEO and President↗
  • Oct 31, 25Compensationamount n/aDAVID J. MACK↗
  • Sep 30, 25Compensationamount n/aDAVID J. MACK↗
  • Sep 15, 25Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Sep 15, 25Compensationamount n/aJavier RodriguezSee Remarks↗
  • Sep 15, 25Compensationamount n/aRichard I SteinhartChief Financial Officer↗
  • Sep 15, 25Compensationamount n/aVimal MehtaCEO and President↗
  • Sep 14, 25Compensationamount n/aFrank YoccaChief Scientific Officer↗
  • Sep 14, 25Compensationamount n/aJavier RodriguezSee Remarks↗

The full record holds 217 transactions and goes back to Nov 15, 22.

Its sector and its market

BioXcel Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From BioXcel Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow BioXcel Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
641 documents on file, from Dec 12, 2017 to Sep 1, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.